ALK and non-small cell lung carcinoma: In ALK-rearranged NSCLC, the ALK-TKIs crizotinib, ceritinib, and more recently alectinib have shown superior response and PFS compared to chemotherapy irrespective of treatment line [7, 8, 9, 10].